BRAINSWAY LTD-ADR

BWAYNASDAQ

🏆 #2460 by market capEarnings Aug 12US Equity

$15.69▲ $0.74 (+4.71%)

Live

1h▲ 2.7%

24h▲ 4.7%

7d▲ 4.0%

14d▲ 10.5%

30d▲ 10.8%

1y▲ 157.1%

🏦Market Cap

$615M

Small Cap

📈Revenue Growth (YoY)

+27.3%

High Growth

📊Gross Margin

75.5%

High

💵FCF Margin

18.5%

Healthy

⚖️P/S Ratio

10.3x

Elevated

Otter Score

Weak

Trading Snapshot

Day Range: $15.50 – $15.81
52-Week Range: $6.25 – $17.35
Volume: $2.54B
Avg Volume: $3.35B
Shares Outstanding: 39.2M
Next Earnings: Oct 9, 2026

Fundamentals Snapshot

Annual Revenue: $52M
Last Q Revenue: $16M
P/E Ratio: 68.9
P/S Ratio: 10.3x
EPS (TTM): $0.46
Dividend Yield: 0.00%

Why Investors Own BWAY

✓High-growth profile — revenue up -6.4% YoY with expanding US Equity exposure.
✓Healthy economics — 62% gross margin and 30% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$52M▼ −6.2% YoY

Gross Margin (TTM)

61.8%▲ +4.4% YoY

Operating Income (TTM)

$9M▼ −6.2% YoY

Free Cash Flow (TTM)

$15M▼ −6.2% YoY

About BRAINSWAY LTD-ADR

BrainsWay Ltd. develops and distributes non-invasive neurostimulation therapies that address a broad spectrum of mental health and neurological conditions. The company operates globally, with a presence in the United States, Europe, and Israel, among other international markets. Its primary offering is the Deep Transcranial Magnetic Stimulation (dTMS) platform technology, which provides treatment for various ailments including major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post-traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post-stroke rehabilitation, and Parkinson's disease. BrainsWay's clientele primarily comprises medical professionals, hospitals, and medical centers specializing in psychiatry. The company was founded in 2003 and is headquartered in Jerusalem, Israel.

🦦